Preface |
|
xiii | |
Introduction |
|
|
Of Model Pets and Cancer Models: An Introduction to Mouse Models of Cancer |
|
|
1 | (16) |
|
|
|
|
|
PART 1 ORIGINS AND HISTORY OF MOUSE MODELS OF CANCER |
|
|
|
|
|
|
|
Transgenic Mouse Models---A Seminal Breakthrough in Oncogene Research |
|
|
17 | (10) |
|
|
|
|
|
|
|
Analyses of Tumor-Suppressor Genes in Germline Mouse Models of Cancer |
|
|
27 | (6) |
|
|
|
|
|
|
|
Conditional Knockout Mouse Models of Cancer |
|
|
33 | (18) |
|
|
|
|
|
|
Animal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 Years |
|
|
51 | (10) |
|
|
|
|
1 Induction of Liver Tumors in Mice with N-Ethyl-N-Nitrosourea or N-Nitrosodiethylamine |
|
|
61 | (2) |
|
|
|
|
2 Induction of Lung Tumors in Mice with Urethane |
|
|
63 | (3) |
|
|
|
|
3 Induction of Colon Cancer in Mice with 1,2-Dimethylhydrazine |
|
|
66 | (3) |
|
|
|
|
|
|
|
|
The Effects of Genetic Background of Mouse Models of Cancer: Friend or Foe? |
|
|
69 | (7) |
|
|
|
|
1 Controlling Genetic Background in Crosses of Mouse Models of Cancer |
|
|
76 | (5) |
|
|
2 Using the Collaborative Cross to Study the Role of Genetic Diversity in Cancer-Related Phenotypes |
|
|
81 | (8) |
|
|
PART 2 RECENT APPROACHES TO MODELING CANCER IN MICE |
|
|
|
|
|
|
|
Genetically Engineered Knock-In and Conditional Knock-In Mouse Models of Cancer |
|
|
89 | (16) |
|
|
|
|
|
|
|
Strategies to Achieve Conditional Gene Mutation in Mice |
|
|
105 | (11) |
|
|
|
|
|
|
1 Producing and Concentrating Lenti-Cre for Mouse Infections |
|
|
116 | (3) |
|
|
|
|
2 In Vivo Delivery of Lenti-Cre or Adeno-Cre into Mice Using Intranasal Instillation |
|
|
119 | (3) |
|
|
|
|
3 Whole-Mount X-Gal Staining of Mouse Tissues |
|
|
122 | (3) |
|
|
|
|
|
|
|
|
Tetracyline-Regulated Mouse Models of Cancer |
|
|
125 | (18) |
|
|
|
|
|
|
|
|
|
The Estrogen Receptor Fusion System in Mouse Models: A Reversible Switch |
|
|
143 | (8) |
|
|
|
|
|
|
|
1 Tamoxifen Administration to Mice |
|
|
151 | (4) |
|
|
|
|
|
|
|
|
Using the RCAS-TVA System to Model Human Cancer in Mice |
|
|
155 | (8) |
|
|
|
|
|
1 Generation of High-Titer RCAS Virus from DF1 Chicken Fibroblasts |
|
|
163 | (6) |
|
|
|
2 In Vivo Delivery of RCAS Virus to Mice |
|
|
169 | (4) |
|
|
|
|
|
|
|
Transposon Insertional Mutagenesis Models of Cancer |
|
|
173 | (14) |
|
|
|
|
|
|
|
|
|
Accelerating Cancer Modeling with RNAi and Nongermline Genetically Engineered Mouse Models |
|
|
187 | (16) |
|
|
|
|
|
|
|
Chimeric Tumor and Organ Transplantation Models |
|
|
203 | (6) |
|
|
|
|
1 Reconstitution of Mice with Modified Hematopoietic Stem Cells |
|
|
209 | (6) |
|
|
2 Reconstitution of Mice with Modified Liver Stem Cells |
|
|
215 | (4) |
|
|
|
3 Syngeneic Transplants with Modified Chimeric Hematopoietic Tumors |
|
|
219 | (5) |
|
|
4 Loss-of-Function Screening in Hematopoietic Malignancies |
|
|
224 | (3) |
|
|
|
|
|
|
Tissue Recombination Models for the Study of Epithelial Cancer |
|
|
227 | (13) |
|
|
|
|
|
|
1 Preparation of Urogenital Sinus Mesenchymal Cells for Prostate Tissue Recombination Models |
|
|
240 | (3) |
|
|
|
|
2 Dissociated Prostate Regeneration Under the Renal Capsule |
|
|
243 | (4) |
|
|
|
|
3 The Cleared Mammary Fat Pad Transplantation Assay for Mammary Epithelial Organogenesis |
|
|
247 | (6) |
|
|
|
|
|
|
|
|
|
Human Cancer Growth and Therapy in Immunodeficient Mouse Models |
|
|
253 | (15) |
|
|
|
|
|
|
|
|
|
1 Subcapsular Transplantation of Tissue in the Kidney |
|
|
268 | (5) |
|
|
|
|
|
|
|
PART 3 ANALYZING MOUSE CANCER PHENOTYPES |
|
|
|
|
|
|
|
Analysis of Mouse Model Pathology: A Primer for Studying the Anatomic Pathology of Genetically Engineered Mice |
|
|
273 | (20) |
|
|
|
|
|
|
|
293 | (4) |
|
|
|
|
|
297 | (3) |
|
|
|
|
3 Manual Hematoxylin and Eosin Staining of Mouse Tissue Sections |
|
|
300 | (4) |
|
|
|
|
4 Manual Immunohistochemistry Staining of Mouse Tissues Using the Avidin--Biotin Complex (ABC) Technique |
|
|
304 | (5) |
|
|
|
|
|
|
|
|
Imaging Mouse Cancer Models In Vivo Using Reporter Transgenes |
|
|
309 | (16) |
|
|
|
|
|
|
|
|
Noninvasive Imaging of Tumor Burden and Molecular Pathways in Mouse Models of Cancer |
|
|
325 | (10) |
|
|
|
|
|
|
|
|
1 18F-FDG-PET/CT Imaging of Drug-Induced Metabolic Changes in Genetically Engineered Mouse Lung Cancer Models |
|
|
335 | (4) |
|
|
|
2 Preclinical Magnetic Resonance Imaging in Mouse Cancer Models |
|
|
339 | (4) |
|
|
|
3 Quantitative Bioluminescence Imaging of Mouse Tumor Models |
|
|
343 | (4) |
|
|
|
|
|
|
|
Methods to Study Metastasis in Genetically Modified Mice |
|
|
347 | (11) |
|
|
|
|
|
|
|
1 Tissue Dissociation for Metastasis Studies |
|
|
358 | (6) |
|
|
|
2 Murine Stem Cell-Based Retrovirus Production for Marking Primary Mouse Mammary Cells for Metastasis Studies |
|
|
364 | (6) |
|
|
|
3 Enrichment of Mammary Basal and Luminal Cells for Cell-of-Origin Metastasis Studies |
|
|
370 | (4) |
|
|
|
|
4 Isolating Epithelial and Epithelial-to-Mesenchymal Transition Populations from Primary Tumors by Fluorescence-Activated Cell Sorting |
|
|
374 | (3) |
|
|
|
|
5 Orthotopic Injection of Pancreatic Cancer Cells |
|
|
377 | (4) |
|
|
|
|
|
|
|
|
Methods for Analysis of the Immune System in Mouse Cancer Models |
|
|
381 | (3) |
|
|
|
|
|
1 Multicolor Flow Cytometric Analysis of Immune Cell Subsets in Tumor-Bearing Mice |
|
|
384 | (6) |
|
|
|
2 Immunohistochemical Assessment of Immune Cells in Mouse Tumor Tissue |
|
|
390 | (6) |
|
|
|
3 A Myeloid-Derived Suppressor Cell-Mediated T-Cell Suppression Assay for Functional Evaluation of Immune Cells in Tumor-Bearing Mice |
|
|
396 | (5) |
|
|
|
|
|
|
|
Culturing Mouse Tumor Cells |
|
|
401 | (3) |
|
|
|
|
|
|
1 Culturing Primary Mouse Pancreatic Ductal Cells |
|
|
404 | (4) |
|
|
|
|
2 Creation of Primary Cell Lines from Lineage-Labeled Mouse Models of Cancer |
|
|
408 | (4) |
|
|
3 Organotypic Culture of Untransformed and Tumorigenic Primary Mammary Epithelial Cells |
|
|
412 | (5) |
|
|
4 Culturing Adult Stem Cells from Mouse Small Intestinal Crypts |
|
|
417 | (5) |
|
|
|
|
|
5 Three-Dimensional Organotypic Culture of Stratified Epithelia |
|
|
422 | (5) |
|
|
|
|
|
|
|
Translational Therapeutics in Genetically Engineered Mouse Models of Cancer |
|
|
427 | (13) |
|
|
|
|
|
1 Acquisition of Mouse Tumor Biopsies through Abdominal Laparotomy |
|
|
440 | (10) |
|
|
|
2 Generation of Drug-Resistant Tumors Using Intermittent Dosing of Tyrosine Kinase Inhibitors in Mouse |
|
|
450 | (5) |
|
|
|
|
|
A Applications For GEMMs In Clinical Research |
|
|
|
Appendix A1 Effective Utilization and Appropriate Selection of Genetically Engineered Mouse Models for Translational Integration of Mouse and Human Trials |
|
|
455 | (6) |
|
|
|
Appendix A2 Infrastructure Needs for Translational Integration of Mouse and Human Trials |
|
|
461 | (6) |
|
|
|
Appendix A3 Structured Reporting in Anatomic Pathology for Coclinical Trials: The caELMIR Model |
|
|
467 | (12) |
|
|
|
|
|
Appendix A4 Mouse to Human Blood-Based Cancer Biomarker Discovery Strategies |
|
|
479 | (6) |
|
|
|
Appendix A5 Evaluation of Cancer Immunity in Mice |
|
|
485 | (4) |
|
|
|
Appendix A6 Cross-Species Analysis of Mouse and Human Cancer Genomes |
|
|
489 | (10) |
|
Carla Daniela Robles-Espinoza |
|
|
|
B General Safety And Hazardous Material Information |
|
|
|
Appendix B General Safety and Hazardous Material Information |
|
|
499 | (6) |
Index |
|
505 | |